Antipsychotics, Metabolic Adverse Effects, and Cognitive Function in Schizophrenia
Open accessThe DOI matches its Crossref record; 137 of the 137 references it cites were found in a registry or an index.
Abstract
Cognitive impairment is a core symptom domain of schizophrenia. The effect of antipsychotics, the cornerstone of treatment in schizophrenia, on this domain is not fully clear. There is some evidence suggesting that antipsychotics may partially improve cognitive function, and that this improvement may vary depending on the specific cognitive domain. However, this research is confounded by various factors, such as age, duration/stage of illness, medication adherence, and extrapyramidal side effects that complicate the relationship between antipsychotics and cognitive improvement. Furthermore, antipsychotics-particularly the second generation, or "atypical" antipsychotics-can induce serious metabolic side effects, such as obesity, dyslipidemia and type 2 diabetes, illnesses which themselves have been linked to impairments in cognition. Thus, the inter-relationships between cognition and metabolic side effects are complex, and this review aims to examine them in the context of schizophrenia and antipsychotic treatment. The review also speculates on potential mechanisms underlying cognitive functioning and metabolic risk in schizophrenia. We conclude that the available literature examining the inter-section of antipsychotics, cognition, and metabolic effects in schizophrenia is sparse, but suggests a relationship between metabolic comorbidity and worse cognitive function in patients with schizophrenia. Further research is required to determine if there is a causal connection between the well-recognized metabolic adverse effects of antipsychotics and cognitive deficits over the course of the illness of schizophrenia, as well as, to determine underlying mechanisms. In addition, findings from this review highlight the importance of monitoring metabolic disturbances in parallel with cognition, as well as, the importance of interventions to minimize metabolic abnormalities for both physical and cognitive health.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alberti, K. G. M. M., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., Donato, K. A., Fruchart, J.-C., James, W. P. T., Loria, C. M., & Smith, S. C. (2009) · Circulation · doi:10.1161/circulationaha.109.192644 · Cited by 14,860
Grundy, S. M., Cleeman, J. I., Daniels, S. R., Donato, K. A., Eckel, R. H., Franklin, B. A., Gordon, D. J., Krauss, R. M., Savage, P. J., Smith, S. C., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.169404 · Cited by 11,961 · cited 1×
“Non-psychiatrically Ill Populations The term metabolic syndrome (MetS) refers to the presence of multiple, interrelated cardiovascular risk factors occurring simultaneously (78, 79).”
BackgroundDE HERT, M., CORRELL, C. U., BOBES, J., CETKOVICH‐BAKMAS, M., COHEN, D., ASAI, I., DETRAUX, J., GAUTAM, S., MÖLLER, H., NDETEI, D. M., et al. (2011) · World Psychiatry · doi:10.1002/j.2051-5545.2011.tb00014.x · Cited by 2,488 · cited 1×
“More recent work, however, suggests that all AP drugs are associated with early significant weight gain (68), particularly in young APnaïve patients (69–72).”
BackgroundAntipsychotic-induced weight gain: a comprehensive research synthesis
Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., & Weiden, P. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1686 · Cited by 2,382
A comprehensive definition for metabolic syndrome
Huang, P. L. (2009) · Disease Models & Mechanisms · doi:10.1242/dmm.001180 · Cited by 2,214 · cited 2×
“Non-psychiatrically Ill Populations The term metabolic syndrome (MetS) refers to the presence of multiple, interrelated cardiovascular risk factors occurring simultaneously (78, 79).”
BackgroundOwen, M. J., Sawa, A., & Mortensen, P. B. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01121-6 · Cited by 1,870
Identification of separable cognitive factors in schizophrenia
Nuechterlein, K. H., Barch, D. M., Gold, J. M., Goldberg, T. E., Green, M. F., & Heaton, R. K. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2004.09.007 · Cited by 1,304 · cited 1×
“These specific domains include speed of processing, attention, working memory, verbal learning and memory, visual learning and memory, reasoning and problem solving, and social cognition (15).”
Backgroundde Leon, J., & Diaz, F. J. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.02.010 · Cited by 1,276 · cited 1×
“There are multiple factors which contribute to the elevated prevalence rate of MetS in the schizophrenia population, including lifestyle factors, such as smoking (91), poor eating habits and sedentary behavior (see Ringen (92) for an in-depth review).”
BackgroundMcEvoy, J. P., Meyer, J. M., Goff, D. C., Nasrallah, H. A., Davis, S. M., Sullivan, L., Meltzer, H. Y., Hsiao, J., Scott Stroup, T., & Lieberman, J. A. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.07.014 · Cited by 1,140 · cited 2×
“Independent studies suggest that about 50% of patients treated with APs develop metabolic complications (4, 5).”
BackgroundMitchell, A. J., Vancampfort, D., Sweers, K., van Winkel, R., Yu, W., & De Hert, M. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbr148 · Cited by 1,082
Schizophrenia and increased risks of cardiovascular disease
Hennekens, C. H., Hennekens, A. R., Hollar, D., & Casey, D. E. (2005) · American Heart Journal · doi:10.1016/j.ahj.2005.02.007 · Cited by 1,070 · cited 1×
“Schizophrenia continues to be associated with severe disability, owing largely to cognitive impairments (2), while metabolic illness contributes to decreased patient lifespan by about 20 years due to cardiovascular disease (8).”
BackgroundKeefe, R. S. E. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.6.633 · Cited by 1,065 · cited 1×
“Additionally, the effect size for improvement in cognition was found to be small (28), with questionable clinical significance (29).”
BackgroundCorrell, C. U. (2009) · JAMA · doi:10.1001/jama.2009.1549 · Cited by 1,050 · cited 1×
“These rates are even higher in young, first episode patients (6, 7).”
BackgroundSchizophrenia, “just the facts” 4. Clinical features and conceptualization
Tandon, R., Nasrallah, H. A., & Keshavan, M. S. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.03.005 · Cited by 1,027
The Effects of Clozapine, Risperidone, and Olanzapine on Cognitive Function in Schizophrenia
Meltzer, H. Y., & McGurk, S. R. (1999) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033376 · Cited by 1,020 · cited 3×
“Clozapine has shown large positive effects in attention and verbal fluency with modest improvements in executive functioning (20) and delayed recall (21).”
BackgroundResultInflammatory cytokine alterations in schizophrenia: a systematic quantitative review
Potvin, S., Stip, E., Sepehry, A. A., Gendron, A., Bah, R., & Kouassi, E. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.09.024 · Cited by 858
Cognitive Impairment in Schizophrenia Is the Core of the Disorder
Elvevag, B., & Goldberg, T. E. (2000) · Critical Reviews™ in Neurobiology · doi:10.1615/critrevneurobiol.v14.i1.10 · Cited by 835 · cited 1×
“An impairment in cognition is a hallmark symptom experienced by individuals with schizophrenia, and has been postulated to be a core aspect of the disorder (11).”
BackgroundLeonard, B., & Maes, M. (2012) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2011.12.005 · Cited by 805 · cited 1×
“For example, genes associated with the illness of schizophrenia have independently been linked to regulation of fat mass, leptin signaling (94), insulin signaling, glucose metabolism, and inflammation (95, 96).”
BackgroundRummel-Kluge, C., Komossa, K., Schwarz, S., Hunger, H., Schmid, F., Lobos, C. A., Kissling, W., Davis, J. M., & Leucht, S. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.07.012 · Cited by 675
Brain Insulin Resistance at the Crossroads of Metabolic and Cognitive Disorders in Humans
Kullmann, S., Heni, M., Hallschmid, M., Fritsche, A., Preissl, H., & Häring, H.-U. (2016) · Physiological Reviews · doi:10.1152/physrev.00032.2015 · Cited by 622 · cited 1×
“Thus, dysregulation or resistance to central insulin action could result in impaired cognition, and indeed, recent work suggests that insulin is the common link between metabolic disorders and disorders of cognition (127).”
BackgroundWoodward, N. D., Purdon, S. E., Meltzer, H. Y., & Zald, D. H. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s146114570500516x · Cited by 605 · cited 3×
“Clozapine has shown large positive effects in attention and verbal fluency with modest improvements in executive functioning (20) and delayed recall (21).”
BackgroundResultStrachan, M. W. J., Deary, I. J., Ewing, F. M. E., & Frier, B. M. (1997) · Diabetes Care · doi:10.2337/diacare.20.3.438 · Cited by 529
Diabetic Microvascular Disease: An Endocrine Society Scientific Statement
Barrett, E. J., Liu, Z., Khamaisi, M., King, G. L., Klein, R., Klein, B. E. K., Hughes, T. M., Craft, S., Freedman, B. I., Bowden, D. W., et al. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01922 · Cited by 515
Hippocampal damage and memory impairments as possible early brain complications of type 2 diabetes
Gold, S. M., Dziobek, I., Sweat, V., Tirsi, A., Rogers, K., Bruehl, H., Tsui, W., Richardson, S., Javier, E., & Convit, A. (2007) · Diabetologia · doi:10.1007/s00125-007-0602-7 · Cited by 489 · cited 1×
“In addition, these two critical domains of health and functioning might interact, as metabolic dysregulation is associated with impaired cognition in both patients with schizophrenia (9), as well as, the non-psychiatrically ill (10).”
BackgroundFirth, J., Stubbs, B., Rosenbaum, S., Vancampfort, D., Malchow, B., Schuch, F., Elliott, R., Nuechterlein, K. H., & Yung, A. R. (2016) · Schizophrenia Bulletin · doi:10.1093/schbul/sbw115 · Cited by 488
Cognitive Impairment in Schizophrenia
Keefe, R. S. E., & Harvey, P. D. (2012) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-25758-2_2 · Cited by 472
Amnesia is a Deficit in Relational Memory
Ryan, J. D., Althoff, R. R., Whitlow, S., & Cohen, N. J. (2000) · Psychological Science · doi:10.1111/1467-9280.00288 · Cited by 460
A review of longitudinal studies of cognitive functions in schizophrenia patients
Rund, B. R. (1998) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033337 · Cited by 451 · cited 1×
“Cognitive functioning in the chronic stage of the illness is sometimes described as static, as even at a minimum of a year follow-up, no significant improvements are evident (48).”
BackgroundImpact of Metabolic Syndrome on Cognition and Brain: A Selected Review of the Literature
Yates, K. F., Sweat, V., Yau, P. L., Turchiano, M. M., & Convit, A. (2012) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.112.252759 · Cited by 444
Schizophrenia, “Just the Facts”: What we know in 2008
Tandon, R., Keshavan, M. S., & Nasrallah, H. A. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.01.022 · Cited by 409
Correll, C. U., Robinson, D. G., Schooler, N. R., Brunette, M. F., Mueser, K. T., Rosenheck, R. A., Marcy, P., Addington, J., Estroff, S. E., Robinson, J., et al. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.1314 · Cited by 384 · cited 1×
“Similar to the trends seen with weight gain, studies published recently show concerning rates of prediabetes (>15%) in first episode patients within 6 months of AP exposure (73), and significantly higher cumulative risk and incidence of type two diabetes (T2D) (74).”
ResultMetabolic-cognitive syndrome: A cross-talk between metabolic syndrome and Alzheimer's disease
Frisardi, V., Solfrizzi, V., Seripa, D., Capurso, C., Santamato, A., Sancarlo, D., Vendemiale, G., Pilotto, A., & Panza, F. (2010) · Ageing Research Reviews · doi:10.1016/j.arr.2010.04.007 · Cited by 357
Ringen, P. A., Engh, J. A., Birkenaes, A. B., Dieset, I., & Andreassen, O. A. (2014) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2014.00137 · Cited by 339 · cited 1×
“There are multiple factors which contribute to the elevated prevalence rate of MetS in the schizophrenia population, including lifestyle factors, such as smoking (91), poor eating habits and sedentary behavior (see Ringen (92) for an in-depth review).”
BackgroundIs schizophrenia a syndrome of accelerated aging?
Kirkpatrick, B., Messias, E., Harvey, P. D., Fernandez-Egea, E., & Bowie, C. R. (2008) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm140 · Cited by 335 · cited 1×
“Like many psychiatric disorders, schizophrenia has been hypothesized to be a syndrome of accelerated aging (137, 138).”
BackgroundAtypical antipsychotics: new directions and new challenges in the treatment of schizophrenia
Kapur, S., & Remington, G. (2001) · Annual Review of Medicine · doi:10.1146/annurev.med.52.1.503 · Cited by 324 · cited 1×
“The degree to which general symptom improvement contributes to the changes in cognitive outcomes seen with AP treatment is an important consideration (38).”
BackgroundSelf-citationMishara, A. L., & Goldberg, T. E. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.01.027 · Cited by 310
Diamant, M., Blaak, E. E., & de Vos, W. M. (2011) · Obesity Reviews · doi:10.1111/j.1467-789x.2010.00797.x · Cited by 308 · cited 1×
“There are several overlapping sites of action among the GMB and APs (124), and some APs have been shown to modulate the composition of the GMB, which incidentally has been shown to cause weight gain (125).”
BackgroundLongitudinal Study of Cognitive Function in First-Episode and Recent-Onset Schizophrenia
Gold, S., Arndt, S., Nopoulos, P., O’Leary, D. S., & Andreasen, N. C. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.9.1342 · Cited by 296 · cited 1×
“Significant improvements also continue to be seen in this population at three (45) and 5-years follow-up (46), supporting the idea that if treatment is adequate in the early stages of psychosis, greater improvements in cognition are evident without later decline (45).”
BackgroundSherwin, E., Sandhu, K. V., Dinan, T. G., & Cryan, J. F. (2016) · CNS Drugs · doi:10.1007/s40263-016-0370-3 · Cited by 295
Green, M. F. (2016) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14074su1c.02 · Cited by 287 · cited 5×
“Cognition and Schizophrenia Cognition is broadly defined as the ability to accurately perceive, attend to, process and remember information (2).”
BackgroundInfluentialGeneral and Specific Cognitive Deficits in Schizophrenia: Goliath Defeats David?
Dickinson, D., Ragland, J. D., Gold, J. M., & Gur, R. C. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.04.005 · Cited by 284 · cited 1×
“There is both a generalized impairment of cognition, as well, as impairment in several specific areas of functioning (14).”
BackgroundCognitive functioning and positive and negative symptoms in schizophrenia
Addington, J., Addington, D., & Maticka-Tyndale, E. (1991) · Schizophrenia Research · doi:10.1016/0920-9964(91)90039-t · Cited by 283 · cited 1×
“The course of these deficits is not completely clear, however, but in general have a weak relationship with positive symptoms, and a stronger association with the severity of negative symptoms (16).”
BackgroundNielsen, R. E., Levander, S., Kjaersdam Telléus, G., Jensen, S. O. W., Østergaard Christensen, T., & Leucht, S. (2015) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12374 · Cited by 270 · cited 2×
“Two recent network based meta-analyses have shed further light on this question (31, 32).”
BackgroundThe microbiome, immunity, and schizophrenia and bipolar disorder.
Dickerson, F., Severance, E., & Yolken, R. (2017) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2016.12.010 · Cited by 268 · cited 1×
“At the phylum level, individuals with schizophrenia appear to have higher proportions of Firmicutes and lower proportions of Bacteroidetes and Actinobacteria in comparison to healthy controls (118).”
BackgroundCastro-Nallar, E., Bendall, M. L., Pérez-Losada, M., Sabuncyan, S., Severance, E. G., Dickerson, F. B., Schroeder, J. R., Yolken, R. H., & Crandall, K. A. (2015) · PeerJ · doi:10.7717/peerj.1140 · Cited by 268 · cited 1×
“Overall, individuals with schizophrenia have been found to have greater species diversity than those without (119).”
BackgroundCohn, T., Prud'homme, D., Streiner, D., Kameh, H., & Remington, G. (2004) · The Canadian Journal of Psychiatry · doi:10.1177/070674370404901106 · Cited by 254
Self-citationType 2 Diabetes Mellitus in Youth Exposed to Antipsychotics: A Systematic Review and Meta-analysis
Galling, B., Roldán, A., Nielsen, R. E., Nielsen, J., Gerhard, T., Carbon, M., Stubbs, B., Vancampfort, D., De Hert, M., Olfson, M., et al. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.2923 · Cited by 224
Bora, E., Akdede, B. B., & Alptekin, K. (2017) · Psychological Medicine · doi:10.1017/s0033291716003366 · Cited by 219
Longitudinal study of symptoms and cognitive function in chronic schizophrenia
Hughes, C., Kumari, V., Soni, W., Das, M., Binneman, B., Drozd, S., O'Neil, S., Mathew, V., & Sharma, T. (2003) · Schizophrenia Research · doi:10.1016/s0920-9964(01)00393-0 · Cited by 214 · cited 2×
“Studies in chronically ill patients often show little improvement in cognitive symptoms with AP treatment; one study which looked at patients with chronic schizophrenia found no cognitive improvement at 6months follow-up, and found that this lack of improvement was independent of positive symptom alleviation, as rated…”
MethodMeyer, J. M., Nasrallah, H. A., McEvoy, J. P., Goff, D. C., Davis, S. M., Chakos, M., Patel, J. K., Keefe, R. S. E., Stroup, T. S., & Lieberman, J. A. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.07.015 · Cited by 210
Zipursky, R. B., Gu, H., Green, A. I., Perkins, D. O., Tohen, M. F., McEvoy, J. P., Strakowski, S. M., Sharma, T., Kahn, R. S., Gur, R. E., et al. (2005) · British Journal of Psychiatry · doi:10.1192/bjp.187.6.537 · Cited by 207 · cited 1×
“These rates are even higher in young, first episode patients (6, 7).”
BackgroundSpinelli, M., Fusco, S., Mainardi, M., Scala, F., Natale, F., Lapenta, R., Mattera, A., Rinaudo, M., Li Puma, D. D., Ripoli, C., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-02221-9 · Cited by 207 · cited 2×
“It is possible that this involves the palmitic acid pathway (128).”
BackgroundOverview and systematic review of studies of microbiome in schizophrenia and bipolar disorder
Nguyen, T. T., Kosciolek, T., Eyler, L. T., Knight, R., & Jeste, D. V. (2018) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2018.01.013 · Cited by 205 · cited 1×
“Brains of schizophrenia patients show evidence of accelerated aging even early on in the illness (123).”
BackgroundAddington, J., Saeedi, H., & Addington, D. E. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.05.008 · Cited by 198
Bahr, S. M., Tyler, B. C., Wooldridge, N., Butcher, B. D., Burns, T. L., Teesch, L. M., Oltman, C. L., Azcarate-Peril, M. A., Kirby, J. R., & Calarge, C. A. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.135 · Cited by 197 · cited 2×
“The interactions between schizophrenia, APs, and the GMB have gained increasing attention over the past few years, however to date only one study has investigated the use of antipsychotic and their effect on the GMB in humans (125).”
BackgroundDrugs with anticholinergic properties: a current perspective on use and safety
Gerretsen, P., & Pollock, B. G. (2011) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2011.579899 · Cited by 194 · cited 2×
“The aspects of cognition which are most commonly impaired include memory and attention (64).”
BackgroundSelf-citationMorgan, V. A., McGrath, J. J., Jablensky, A., Badcock, J. C., Waterreus, A., Bush, R., Carr, V., Castle, D., Cohen, M., Galletly, C., et al. (2014) · Psychological Medicine · doi:10.1017/s0033291713002973 · Cited by 191
Hypothalamic-Pituitary-Adrenal Axis Dysregulation and Memory Impairments in Type 2 Diabetes
Bruehl, H., Rueger, M., Dziobek, I., Sweat, V., Tirsi, A., Javier, E., Arentoft, A., Wolf, O. T., & Convit, A. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2540 · Cited by 184
Genomics of schizophrenia: time to consider the gut microbiome?
Dinan, T. G., Borre, Y. E., & Cryan, J. F. (2014) · Molecular Psychiatry · doi:10.1038/mp.2014.93 · Cited by 175
Microvascular Dysfunction and Cognitive Impairment
De Silva, T. M., & Faraci, F. M. (2016) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-015-0308-1 · Cited by 171 · cited 1×
“Microangiopathic changes in the brain have been implicated in cognitive decline (135).”
BackgroundAtypical antipsychotics: are some more atypical than others?
Remington, G. J., & Kapur, S. (2000) · Psychopharmacology · doi:10.1007/s002130050017 · Cited by 170 · cited 1×
“Dysregulation Although “atypical” or SGAs, as a class were associated with higher metabolic risk than first-generation antipsychotics, a more nuanced understanding of this “class” [which in itself has become a topic of controversy (65, 66)], has shown that there is a differential metabolic liability [i.”
BackgroundSelf-citationBrain Age in Early Stages of Bipolar Disorders or Schizophrenia
Hájek, T., Franke, K., Kolenič, M., Capkova, J., Matějka, M., Propper, L., Uher, R., Stopková, P., Novák, T., Paus, T., et al. (2017) · Schizophrenia Bulletin · doi:10.1093/schbul/sbx172 · Cited by 165 · cited 1×
“While the focus has been on AP-related metabolic dysregulation, we are reminded that lifestyle factors (smoking, dietary habits, activity levels) also play a critical role in accumulation of metabolic risk in severe mental illness, and both the primary disorder, as well as, accumulation of metabolic risk has been show…”
BackgroundLong-term neurocognitive effects of antipsychotics in schizophrenia: a network meta-analysis
Désaméricq, G., Schurhoff, F., Meary, A., Szöke, A., Macquin-Mavier, I., Bachoud-Lévi, A. C., & Maison, P. (2014) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-013-1600-y · Cited by 161
Keefe, R. S. E. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13065su1.02 · Cited by 153 · cited 5×
“A recent review suggests that the small cognitive improvement seen after AP treatment initiation is possibly due to an improvement in psychotic symptoms, and that there is not much further improvement in cognitive outcomes beyond the first 1–2 years of treatment (12).”
BackgroundInfluentialProcessing and short-term retention of relational information in amnesia
Ryan, J. D., & Cohen, N. J. (2003) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2003.08.011 · Cited by 142
Ott, V., Benedict, C., Schultes, B., Born, J., & Hallschmid, M. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01490.x · Cited by 139 · cited 1×
“Intranasal insulin, which delivers insulin directly to the CNS, is demonstrated to enhance declarative and working memory (126).”
BackgroundRajkumar, A. P., Horsdal, H. T., Wimberley, T., Cohen, D., Mors, O., Børglum, A. D., & Gasse, C. (2017) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.16040442 · Cited by 137
Irani, F., Kalkstein, S., Moberg, E. A., & Moberg, P. J. (2011) · Schizophrenia Bulletin · doi:10.1093/schbul/sbq057 · Cited by 132
Walker, J., & Harrison, F. (2015) · Nutrients · doi:10.3390/nu7095341 · Cited by 126
Pérez‐Iglesias, R., Crespo‐Facorro, B., Martínez‐García, O., Ramírez-Bonilla, M. L., Álvarez‐Jiménez, M., Pelayo‐Terán, J. M., García‐Unzueta, M. T., Amado, J., & Vázquez‐Barquero, J. L. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.10.022 · Cited by 121 · cited 2×
“8 kg weight gain within the first 3 months of treatment (70).”
BackgroundRelationship between metabolic syndrome and cognition in patients with schizophrenia
Lindenmayer, J. P., Khan, A., Kaushik, S., Thanju, A., Praveen, R., Hoffman, L., Cherath, L., Valdez, G., & Wance, D. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.09.019 · Cited by 115 · cited 4×
“MetS has a negative impact on cognition, and indeed schizophrenia patients with MetS have been reported to perform worse on measures of cognition than those with schizophrenia in the absence of MetS (9, 99, 100).”
BackgroundInfluentialTakeuchi, H., Suzuki, T., Remington, G., Bies, R. R., Abe, T., Graff-Guerrero, A., Watanabe, K., Mimura, M., & Uchida, H. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbt090 · Cited by 114
Self-citationExtrapyramidal Side Effects of Antipsychotic Treatment: Scope of Problem and Impact on Outcome
Tandon, R., & Jibson, M. D. (2002) · Annals of Clinical Psychiatry · doi:10.1023/a:1016811222688 · Cited by 114
Malan‐Müller, S., Kilian, S., van den Heuvel, L. L., Bardien, S., Asmal, L., Warnich, L., Emsley, R. A., Hemmings, S. M. J., & Seedat, S. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.11.011 · Cited by 113 · cited 3×
“The serotonin receptor gene 5HT2A has been found to influence both lipid levels and glucose intolerance (94), as well as, attention span and cognitive flexibility (97).”
BackgroundRaben, A. T., Marshe, V. S., Chintoh, A., Gorbovskaya, I., Müller, D. J., & Hahn, M. K. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00741 · Cited by 113
Self-citationOgino, S., Miyamoto, S., Miyake, N., & Yamaguchi, N. (2014) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12088 · Cited by 111 · cited 2×
“Of note, cognition improves when anticholinergic treatment is discontinued (36, 63).”
BackgroundObesity, dyslipidemia and brain age in first-episode psychosis
Kolenič, M., Franke, K., Hlinka, J., Matějka, M., Capkova, J., Pausová, Z., Uher, R., Alda, M., Španiel, F., & Hájek, T. (2018) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2018.02.012 · Cited by 109 · cited 1×
“While the focus has been on AP-related metabolic dysregulation, we are reminded that lifestyle factors (smoking, dietary habits, activity levels) also play a critical role in accumulation of metabolic risk in severe mental illness, and both the primary disorder, as well as, accumulation of metabolic risk has been show…”
BackgroundStriatal dopamine regulates systemic glucose metabolism in humans and mice
ter Horst, K. W., Lammers, N. M., Trinko, R., Opland, D. M., Figee, M., Ackermans, M. T., Booij, J., van den Munckhof, P., Schuurman, P. R., Fliers, E., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aar3752 · Cited by 106
Ramaekers, J. G., Louwerens, J. W., Muntjewerff, N. D., Milius, H., de Bie, A., Rosenzweig, P., Patat, A., & O'Hanlon, J. F. (1999) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199906000-00003 · Cited by 105
Transcriptome analysis in whole blood reveals increased microbial diversity in schizophrenia
Olde Loohuis, L. M., Mangul, S., Ori, A. P. S., Jospin, G., Koslicki, D., Yang, H. T., Wu, T., Boks, M. P., Lomen-Hoerth, C., Wiedau-Pazos, M., et al. (2018) · Translational Psychiatry · doi:10.1038/s41398-018-0107-9 · Cited by 103
Central Proliferation and Neurogenesis Is Impaired in Type 2 Diabetes and Prediabetes Animal Models
Ramos-Rodriguez, J. J., Molina-Gil, S., Ortiz-Barajas, O., Jimenez-Palomares, M., Perdomo, G., Cozar-Castellano, I., Lechuga-Sancho, A. M., & Garcia-Alloza, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089229 · Cited by 103 · cited 1×
“Insulin resistance has been shown to be associated with impaired hippocampal synaptic plasticity and memory (128), as well as, neurogenesis (129).”
BackgroundHusa, A. P., Rannikko, I., Moilanen, J. S., Haapea, M., Murray, G. K., Barnett, J. H., Jones, P. B., Isohanni, M. K., Koponen, H., Miettunen, J., et al. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.06.035 · Cited by 102 · cited 2×
“Interestingly, there were no significant differences in cognitive decline observed between low-dose cases and non-psychiatric controls over the 9-years naturalistic follow up (50).”
BackgroundBartzokis, G., Lu, P. H., Amar, C. P., Raven, E. P., Detore, N. R., Altshuler, L. L., Mintz, J., Ventura, J., Casaus, L. R., Luo, J. S., et al. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.06.029 · Cited by 96 · cited 2×
“This was attributed to adherence to medication (58) and suggests that perhaps adherence to treatment may impact the extent to which cognitive benefits are seen.”
BackgroundDepp, C. A., Strassnig, M., Mausbach, B. T., Bowie, C. R., Wolyniec, P. S., Thornquist, M. H., Luke, J. R., McGrath, J. A., Pulver, A. E., Patterson, T. L., et al. (2014) · Bipolar Disorders · doi:10.1111/bdi.12200 · Cited by 95 · cited 3×
“(142) found that aerobic exercise improved cognitive functioning in patients in schizophrenia (104).”
BackgroundAccelerated aging in schizophrenia and related disorders: Future research
Kirkpatrick, B. W., & Kennedy, B. K. (2017) · Schizophrenia Research · doi:10.1016/j.schres.2017.06.034 · Cited by 94
Body weight and self-esteem in patients with schizophrenia evaluated with B-WISE®
Binder, M. D., Peuskens, B., van Winkel, R., Kalnická, D., Hanssens, L., Eyck, D. V., Wyckaert, S., & Peuskens, J. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.07.025 · Cited by 93
Labazi, H., & Trask, A. J. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.07.004 · Cited by 93 · cited 1×
“Microangiopathy is a well-known consequence of metabolic abnormalities including diabetes and metabolic syndrome (132, 133), and is closely related with the development of insulin resistance (134).”
BackgroundPérez‐Iglesias, R., Vázquez‐Barquero, J. L., Amado, J., Berja, A., García‐Unzueta, M. T., Pelayo‐Terán, J. M., Carrasco-Marín, E., Mata, I. F., & Crespo‐Facorro, B. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318172b8e6 · Cited by 90
Overeating Behavior and Striatal Dopamine with 6--Fluoro-L--Tyrosine PET
Wilcox, C. E., Braskie, M. N., Kluth, J. T., & Jagust, W. J. (2010) · Journal of Obesity · doi:10.1155/2010/909348 · Cited by 87
Graff-Guerrero, A., Rajji, T. K., Mulsant, B. H., Nakajima, S., Caravaggio, F., Suzuki, T., Uchida, H., Gerretsen, P., Mar, W., Pollock, B. G., et al. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.0891 · Cited by 86
Self-citationAntipsychotics and glucose metabolism: how brain and body collide
Kowalchuk, C., Castellani, L. N., Chintoh, A., Remington, G., Giacca, A., & Hahn, M. K. (2019) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00164.2018 · Cited by 85
Self-citationCardiovascular Risk Factors and Cognitive Function in Adults 30–59 Years of Age (NHANES III)
Pavlik, V. N., Hyman, D. J., & Doody, R. (2005) · Neuroepidemiology · doi:10.1159/000081049 · Cited by 85
Rajji, T. K., Mulsant, B. H., Davies, S., Kalache, S. M., Tsoutsoulas, C., Pollock, B. G., & Remington, G. J. (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.14050673 · Cited by 82 · cited 1×
“Hence, it is quite plausible that the effects of APs on cognition and metabolic measures are really two sides of the same coin: as binding to a given receptor leads to downstream effects on both domains (110).”
BackgroundSelf-citationCaravaggio, F., Borlido, C., Hahn, M., Feng, Z., Fervaha, G., Gerretsen, P., Nakajima, S., Plitman, E., Chung, J. K., Iwata, Y., et al. (2015) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv014 · Cited by 81 · cited 1×
“For instance, acute dopamine depletion in humans and rodents reduces peripheral insulin sensitivity (111, 112), purportedly via central dopamine effects in the striatum.”
BackgroundSelf-citationThe microbiome-gut-brain axis: implications for schizophrenia and antipsychotic induced weight gain
Kanji, S., Fonseka, T. M., Marshe, V. S., Sriretnakumar, V., Hahn, M. K., & Müller, D. J. (2018) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-017-0820-z · Cited by 79
Self-citationHypertension and Hypothalamo-Pituitary-Adrenal Axis Hyperactivity Affect Frontal Lobe Integrity
Gold, S. M., Dziobek, I., Rogers, K., Bayoumy, A., McHugh, P. F., & Convit, A. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2181 · Cited by 79 · cited 1×
“For example, patients with hypertension performed significantly worse on executive functioning tasks, which was correlated with reduced frontal lobe volume and impaired glucocorticoid feedback (87).”
BackgroundChen, D. C., Du, X., Yin, G. Z., Yang, K., Nie, Y., Wang, N., Li, Y., Xiu, M., He, S. C., Yang, F. D., et al. (2016) · Psychological Medicine · doi:10.1017/s0033291716001902 · Cited by 78
Insulin: An Emerging Treatment for Alzheimer’s Disease Dementia?
Morris, J. K., & Burns, J. M. (2012) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-012-0297-0 · Cited by 71 · cited 1×
“Furthermore, addressing this pathology via administration of insulin intranasally is emerging as a possible treatment strategy in Alzheimer’s dementia (130).”
BackgroundLipkovich, I. A., Deberdt, W., Csernansky, J. G., Sabbe, B., Keefe, R. S., & Kollack-Walker, S. (2009) · BMC Psychiatry · doi:10.1186/1471-244x-9-44 · Cited by 67
Roffman, J. L., Weiss, A. P., Deckersbach, T., Freudenreich, O., Henderson, D. C., Purcell, S., Wong, D. H., Halsted, C. H., & GOFF, D. C. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.01.003 · Cited by 67 · cited 1×
“As well, the methylenetetrahydrofolate reductase (MTHFR) gene is believed to increase the susceptibility of developing MetS in patients with schizophrenia (94), and is also implicated in poorer verbal recall and cognitive flexibility (98).”
BackgroundLv, F., Chen, S., Wang, L., Jiang, R., Tian, H., Li, J., Yao, Y., & Zhuo, C. (2017) · Oncotarget · doi:10.18632/oncotarget.21284 · Cited by 66 · cited 1×
“When looking solely at the interplay between the GMB and schizophrenia, it appears that abnormalities in the GMB contribute to the production of key molecules (such as Brain-derived neurotrophic factor) and/or the promotion of an intestinal immune response (120).”
BackgroundRiedel, M. J., Spellmann, I., Strassnig, M., Douhet, A., Dehning, S., Opgen-Rhein, M., Valdevit, R., Engel, R. R., Kleindienst, N., Müller, N., et al. (2007) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-007-0739-x · Cited by 66
Czepielewski, L. S., Wang, L., Gama, C. S., & Barch, D. M. (2016) · Schizophrenia Bulletin · doi:10.1093/schbul/sbw090 · Cited by 65 · cited 1×
“The accretion of structural changes in the brain (with illness progression, treatment, and metabolic abnormalities) may also contribute to this relationship, as cognitive performance has been shown to be associated with lower gray matter volume (108, 109).”
BackgroundBoyer, L., Richieri, R. M., Dassa, D., Boucékine, M., Fernandez, J., Vaillant, F., Padovani, R., Auquier, P., & Lançon, C. (2013) · Psychiatry Research · doi:10.1016/j.psychres.2013.06.020 · Cited by 64 · cited 1×
“Similar results were also seen in a study by Boyer et al, who found that longer disease duration was correlated with increased rates of MetS, and this was subsequently correlated with worse cognitive impairment, which was particularly robust in individuals taking second generation APs (106).”
ResultBender, S., Dittmann-Balçar, A., Schall, U., Wolstein, J. R., Klimke, A., Riedel, M. J., Vorbach, E.-U., Kühn, K.-U., Lambert, M., Dittmann, R., et al. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145705005924 · Cited by 61
Relationship of Cognition to Clinical Response in First-Episode Schizophrenia Spectrum Disorders
Trampush, J. W., Lencz, T., DeRosse, P., John, M., Gallego, J. A., Petrides, G., Hassoun, Y., Zhang, J., Addington, J., Kellner, C. H., et al. (2015) · Schizophrenia Bulletin · doi:10.1093/schbul/sbv120 · Cited by 60 · cited 1×
“In firstepisode patients, significant improvement in cognition has been reported across many studies and small but significant cognitive improvements related to AP treatment have been seen in first-episode patients as early as 3 months into treatment, in correlation with positive symptom alleviation (44).”
BackgroundAnticholinergics in the era of atypical antipsychotics: short-term or long-term treatment?
Desmarais, J. E., Beauclair, L., & Margolese, H. C. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112447988 · Cited by 59 · cited 2×
“Of note, cognition improves when anticholinergic treatment is discontinued (36, 63).”
BackgroundKRAKOWSKI, M. I., & Czobor, P. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.04.005 · Cited by 59 · cited 1×
“Triglycerides have also been shown to correlate with poorer cognition scores (100), however this effect has been shown to cease to exist when cholesterol is controlled for (107).”
BackgroundVoruganti, L. P., AWAD, A., PARKER, G., Forrest, C. B., USMANI, Y., Fernando, M. L. D., & SENTHILAL, S. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.08.002 · Cited by 57
Jann, M. W. (2004) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.24.17.1759.52346 · Cited by 56 · cited 1×
“Indeed, soon after the introduction of the newer APs, several studies seemed to suggest that treatment with these compounds could improve cognitive functioning in schizophrenia patients (18, 19).”
BackgroundComparing cognitive functions in medication adherent and non-adherent patients with schizophrenia
El-Missiry, A., Elbatrawy, A. N., Missiry, M. E., Moneim, D. A., Ali, R., & Essawy, H. (2015) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2015.09.006 · Cited by 56 · cited 1×
“not take their medications regularly (37).”
Typical and Atypical Antipsychotics – The Misleading Dichotomy
Fischer-Barnicol, D., Lanquillon, S., Haen, E., Zöfel, P., Koch, H. J., Dose, M., & Klein, H. E. (2008) · Neuropsychobiology · doi:10.1159/000135641 · Cited by 55
Diabetes is associated with lower global cognitive function in schizophrenia
Takayanagi, Y., Cascella, N. G., Sawa, A., & Eaton, W. W. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.08.034 · Cited by 53 · cited 1×
“, hypertension) were correlated with lower cognitive scores, whereas other factors, such as increased waist circumference and dyslipidemia were less consistently associated with general impairments in cognition in schizophrenia (49, 103).”
BackgroundFagiolini, A. M., Rocca, P., Giorgi, S. D., Spina, E., Amodeo, G., & Amore, M. (2016) · Psychiatry Research · doi:10.1016/j.psychres.2016.11.044 · Cited by 52 · cited 1×
“Further to this point, a recent review has shown that long acting injectable (LAI) agents show superiority in terms of efficacy when compared to oral agents (56), with reported improvement in general cognitive performance in individuals switching from oral to injectable agents (57).”
BackgroundHeinrichs, R. W. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.6.631 · Cited by 51
Atypical antipsychotics and effects on feeding: from mice to men
Benarroch, L., Kowalchuk, C., Wilson, V. S., Teo, C., Guenette, M. D., Chintoh, A. F., Nesarajah, Y., Taylor, V. H., Selby, P. L., Fletcher, P. J., et al. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4324-8 · Cited by 46
Self-citationExtrapyramidal symptoms and cognitive test performance in patients with schizophrenia
Fervaha, G., Agid, O., Takeuchi, H., Lee, J., Foussias, G., Zakzanis, K. K., Graff‐Guerrero, A., & Remington, G. J. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.11.018 · Cited by 44 · cited 1×
“While these sideeffects have been found to be correlated with impaired cognitive abilities, such as set-shifting (59), it appears that cognitive impairments may be associated with EPS even in the absence of active antipsychotic treatment (35).”
BackgroundSelf-citationBervoets, C., Morrens, M., Vansteelandt, K., Kok, F., de Patoul, A., Halkin, V., Pitsi, D., Constant, E., Peuskens, J., & Sabbe, B. (2012) · CNS Drugs · doi:10.1007/s40263-012-0003-4 · Cited by 44
Rémillard, S., Pourcher, E., & Cohen, H. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.07.026 · Cited by 40
Li, C., Zhan, G., Rao, S., & Zhang, H. (2014) · The Journal of Nervous and Mental Disease · doi:10.1097/nmd.0000000000000124 · Cited by 40 · cited 3×
“MetS has a negative impact on cognition, and indeed schizophrenia patients with MetS have been reported to perform worse on measures of cognition than those with schizophrenia in the absence of MetS (9, 99, 100).”
BackgroundResultLower dopamine tone in the striatum is associated with higher body mass index
Lee, Y., Kroemer, N. B., Oehme, L., Beuthien‐Baumann, B., Goschke, T., & Smolka, M. N. (2018) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2018.03.009 · Cited by 40
Kim, S., Shin, I., Kim, J., Lee, S., Lee, Y., Yang, S., & Yoon, J. (2009) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.1057 · Cited by 38 · cited 1×
“Further to this point, a recent review has shown that long acting injectable (LAI) agents show superiority in terms of efficacy when compared to oral agents (56), with reported improvement in general cognitive performance in individuals switching from oral to injectable agents (57).”
BackgroundÜçok, A., Alpsan, H., Çakır, S., & Saruhan‐Direskeneli, G. (2007) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30463 · Cited by 37 · cited 1×
“The serotonin receptor gene 5HT2A has been found to influence both lipid levels and glucose intolerance (94), as well as, attention span and cognitive flexibility (97).”
BackgroundAssociations Between Components of Metabolic Syndrome and Cognition in Patients With Schizophrenia
S. GOUGHARI, A., MAZHARI, S., POURRAHIMI, A. M., SADEGHI, M. M., & NAKHAEE, N. (2015) · Journal of Psychiatric Practice · doi:10.1097/pra.0000000000000065 · Cited by 35 · cited 5×
“The dose of AP medication may have an effect on cognition, with higher AP doses, as well as, AP polypharmacy, reported to be associated with worse cognitive functioning (49, 50).”
BackgroundInfluentialJoshua, N. R., Gogos, A., & Rossell, S. L. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.05.029 · Cited by 35
Zipursky, R. B., Christensen, B. K., Daskalakis, Z. J., Epstein, I., Roy, P., Furimsky, I., Sanger, T. M., & Kapur, S. (2005) · The Canadian Journal of Psychiatry · doi:10.1177/070674370505000806 · Cited by 33
Clozapine improves the orienting of attention in schizophrenia
Spagna, A., Dong, Y., Mackie, M., Li, M., Harvey, P. D., Tian, Y., Wang, K., & Fan, J. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.08.009 · Cited by 31
Caravaggio, F., Borlido, C., Wilson, A. A., & Graff‐Guerrero, A. (2015) · Clinica Chimica Acta · doi:10.1016/j.cca.2015.03.020 · Cited by 29
Self-citationArvanitis, A., Reinders, A. A. T. S., Handley, R., Marques, T. R., Taylor, H., O’Daly, O., McQueen, G., Hubbard, K., Mondelli, V., Pariante, C. M., et al. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.02.023 · Cited by 29
Cognitive performance is associated with gray matter decline in first-episode psychosis
Dempster, K., Norman, R. M. G., Théberge, J., Densmore, M., Schaefer, B., & Williamson, P. (2017) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2017.04.007 · Cited by 28 · cited 1×
“The accretion of structural changes in the brain (with illness progression, treatment, and metabolic abnormalities) may also contribute to this relationship, as cognitive performance has been shown to be associated with lower gray matter volume (108, 109).”
BackgroundJohnsen, E., Jørgensen, H. A., Kroken, R. A., & Løberg, E. ‐. (2011) · European Psychiatry · doi:10.1016/j.eurpsy.2011.10.003 · Cited by 26
Cognition and Dopamine D2 Receptor Availability in the Striatum in Older Patients with Schizophrenia
Rajji, T. K., Mulsant, B. H., Nakajima, S., Caravaggio, F., Suzuki, T., Uchida, H., Gerretsen, P., Mar, W., Pollock, B. G., Mamo, D. C., et al. (2016) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2016.08.001 · Cited by 25
Self-citationMALLA, A. K., Norman, R. M. G., Scholten, D. J., Townsend, L. A., Manchanda, R., Takhar, J., & Haricharan, R. (2004) · Psychiatry Research · doi:10.1016/j.psychres.2004.07.008 · Cited by 25
Insulin resistance in diabetic microangiopathies
Suzuki, M., Kanazawa, A., Shiba, M., Kojima, H., & Harano, Y. (2000) · Journal of Diabetes and its Complications · doi:10.1016/s1056-8727(00)00052-0 · Cited by 22 · cited 1×
“Microangiopathy is a well-known consequence of metabolic abnormalities including diabetes and metabolic syndrome (132, 133), and is closely related with the development of insulin resistance (134).”
BackgroundBody composition, pre‐diabetes and cardiovascular disease risk in early schizophrenia
Strassnig, M., Clarke, J., Mann, S. W., Remington, G. J., & Ganguli, R. (2015) · Early Intervention in Psychiatry · doi:10.1111/eip.12225 · Cited by 15 · cited 1×
“Patients with schizophrenia have an increased risk of diabetes and experience an earlier onset of this illness (139).”
BackgroundSelf-citationCognitive Efficacy of Quetiapine in Early-Onset First-Episode Psychosis: A 12-Week Open Label Trial
Urben, S., Baumann, P., Barcellona, S., Hafil, M., Preuss, U., Peter-Favre, C., Clarke, S., Halfon, O., & Holzer, L. (2011) · Psychiatric Quarterly · doi:10.1007/s11126-011-9201-3 · Cited by 14
Exploration of the associations between neurocognitive function and neuroleptics side effects
Hwang, S. S., Kim, Y., Yun, D. Y., Kim, Y. S., & Jung, H. Y. (2012) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2012.04.005 · Cited by 10 · cited 1×
“While these sideeffects have been found to be correlated with impaired cognitive abilities, such as set-shifting (59), it appears that cognitive impairments may be associated with EPS even in the absence of active antipsychotic treatment (35).”
Background
Cited by
Rotella, F., Cassioli, E., Calderani, E., Lazzeretti, L., Ragghianti, B., Ricca, V., & Mannucci, E. (2020) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2019.12.118 · Cited by 48
Association between lipid metabolism and cognitive function in patients with schizophrenia
Liu, H., Huang, Z., Zhang, X., He, Y., Gu, S., Mo, D., Wang, S., Yuan, Z., Huang, Y., Zhong, Q., et al. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1013698 · Cited by 40
Sahpolat, M., Ayar, D., Ari, M., & Karaman, M. A. (2021) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2021.19.1.112 · Cited by 31
“Previous studies also indicated the inflammation in MetS had a significant role on cognitive impairment [7].”
Result
Metadata
- Authors
- MacKenzie, N. E., Kowalchuk, C., Agarwal, S. M., Costa-Dookhan, K. A., Caravaggio, F., Gerretsen, P., Chintoh, A., Remington, G. J., Taylor, V. H., Müeller, D. J., Graff-Guerrero, A., & Hahn, M. K.
- Venue
- Frontiers in Psychiatry
- Publisher
- Frontiers Media SA
- Published
- 2018-12-05
- Volume
- 9
- Pages
- 622-622
- ISSN
- 1664-0640 (ISSN-L)
- OpenAlex
- W2902303283
- Cited by
- 205
- References
- 137
- FWCI
- 11.97
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.